<DOC>
	<DOCNO>NCT02677896</DOCNO>
	<brief_summary>The purpose study evaluate efficacy enzalutamide plus androgen deprivation therapy ( ADT ) measure radiographic progression-free survival ( rPFS ) base central review . The study also evaluate safety enzalutamide plus ADT mHSPC .</brief_summary>
	<brief_title>A Study Enzalutamide Plus Androgen Deprivation Therapy ( ADT ) Versus Placebo Plus ADT Patients With Metastatic Hormone Sensitive Prostate Cancer ( mHSPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Subject consider adult accord local regulation time sign informed consent . Subject diagnose histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation , signet cell small cell histology . Subject metastatic prostate cancer document positive bone scan metastatic lesion compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan . Subjects whose disease spread limit regional pelvic lymph node eligible . Once randomized day 1 , subject must maintain ADT LHRH agonist antagonist study treatment history bilateral orchiectomy ( i.e. , medical surgical castration ) . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subject receive prior pharmacotherapy , radiation therapy surgery metastatic prostate cancer ( follow exception permit ) : Up 3 month ADT LHRH agonists antagonist orchiectomy without concurrent antiandrogens prior day 1 , radiographic evidence disease progression rise PSA level prior day 1 ; Subject may 1 course palliative radiation surgical therapy treat symptom result metastatic disease administer least 4 week prior day 1 ; Up 6 cycle docetaxel therapy final treatment administration complete within 2 month day 1 evidence disease progression completion docetaxel therapy ; Up 6 month ADT LHRH agonists antagonist orchiectomy without concurrent antiandrogens prior day 1 subject treat docetaxel , radiographic evidence disease progression rise PSA level prior day 1 ; Prior ADT give &lt; 39 month duration &gt; 9 month randomization neoadjuvant/adjuvant therapy . Subject major surgery within 4 week prior day 1 . Subject receive treatment 5α reductase inhibitor ( finasteride , dutasteride ) within 4 week prior day 1 . Subject receive treatment estrogen , cyprotoerone acetate androgen within 4 week prior day 1 . Subject receive treatment systemic glucocorticoid great equivalent 10 mg per day prednisone within 4 week prior day 1 . Subject receive treatment herbal medication know hormonal antiprostate cancer activity and/or know decrease PSA level within 4 week prior day 1 . Subject receive prior aminoglutethimide , ketoconazole , abiraterone acetate enzalutamide treatment prostate cancer participation clinical study investigational agent inhibits AR androgen synthesis ( e.g. , TAK700 , ARN509 , ODM201 ) . Subject know suspected brain metastasis active leptomeningeal disease . Subject absolute neutrophil count &lt; 1500/μL , platelet count &lt; 100000/μL hemoglobin &lt; 10 g/dL ( 6.2 mmol/L ) . Subject total bilirubin ( TBL ) ≥ 1.5 x upper limit normal ( ULN ) ( except subject document Gilbert 's disease ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5 x ULN . Subject creatinine &gt; 2 mg/dL ( 177 μmol/L ) . Subject albumin &lt; 3.0 g/dL ( 30 g/L ) . Subject history seizure condition may predispose seizure . Subject history loss consciousness transient ischemic attack within 12 month prior day 1 . Subject clinically significant cardiovascular disease . Subject receive bisphosphonates denosumab within 2 week prior day 1 unless administer stable dose treat diagnose osteoporosis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Androgen Deprivation Therapy ( ADT )</keyword>
	<keyword>Metastatic hormone sensitive prostate cancer</keyword>
	<keyword>Xtandi</keyword>
	<keyword>Enzalutamide</keyword>
</DOC>